[go: up one dir, main page]

BR0109851A - Composto, método para produzir o mesmo ou um sal deste, pró medicamento, composição farmacêutica, método para inibir a tirosina cinase, método para prevenir ou tratar câncer, e, uso de um composto ou de um sal ou pró medicamento deste - Google Patents

Composto, método para produzir o mesmo ou um sal deste, pró medicamento, composição farmacêutica, método para inibir a tirosina cinase, método para prevenir ou tratar câncer, e, uso de um composto ou de um sal ou pró medicamento deste

Info

Publication number
BR0109851A
BR0109851A BR0109851-9A BR0109851A BR0109851A BR 0109851 A BR0109851 A BR 0109851A BR 0109851 A BR0109851 A BR 0109851A BR 0109851 A BR0109851 A BR 0109851A
Authority
BR
Brazil
Prior art keywords
salt
compound
prodrug
tyrosine kinase
producing
Prior art date
Application number
BR0109851-9A
Other languages
English (en)
Inventor
Akihiro Tasaka
Takenori Hitaka
Etsuya Matsutani
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of BR0109851A publication Critical patent/BR0109851A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"COMPOSTO, MéTODO PARA PRODUZIR O MESMO OU UM SAL DESTE, PRó MEDICAMENTO, COMPOSIçãO FARMACêUTICA, MéTODO PARA INIBIR A TIROSINA CINASE MéTODO PARA PREVENIR OU TRATAR CâNCER, E, USO DE UM COMPOSTO OU DE UM SAL OU PRó MEDICAMENTO DESTE". Um composto representado pela fórmula (1): em que m é 1 ou 2, R^ 1^ é um halógeno ou um alquila C~ 1-2~ opcionalmente halogenado; um de R^ 2^ e R^ 3^ é um átomo de hidrogênio e o outro é um grupo representado pelas fórmulas (2) ou (3): em que n é 3 ou 4; R^ 4^ é um grupo alquila C~ 1-4~ substituído por 1 ou 2 grupos hidróxi, ou um sal deste apresenta atividade inibidora de tirosina cinase.
BR0109851-9A 2000-04-07 2001-04-05 Composto, método para produzir o mesmo ou um sal deste, pró medicamento, composição farmacêutica, método para inibir a tirosina cinase, método para prevenir ou tratar câncer, e, uso de um composto ou de um sal ou pró medicamento deste BR0109851A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000106836 2000-04-07
PCT/JP2001/002937 WO2001077107A1 (en) 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BR0109851A true BR0109851A (pt) 2003-06-03

Family

ID=18619943

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109851-9A BR0109851A (pt) 2000-04-07 2001-04-05 Composto, método para produzir o mesmo ou um sal deste, pró medicamento, composição farmacêutica, método para inibir a tirosina cinase, método para prevenir ou tratar câncer, e, uso de um composto ou de um sal ou pró medicamento deste

Country Status (19)

Country Link
US (2) US6716863B2 (pt)
EP (1) EP1268473A1 (pt)
KR (1) KR20020028865A (pt)
CN (1) CN1444582A (pt)
AU (1) AU2001244726A1 (pt)
BR (1) BR0109851A (pt)
CA (1) CA2404760A1 (pt)
CO (1) CO5261589A1 (pt)
CZ (1) CZ20023264A3 (pt)
EE (1) EE200200576A (pt)
HU (1) HUP0300434A3 (pt)
IL (1) IL152115A0 (pt)
MX (1) MXPA02009621A (pt)
NO (1) NO20024742L (pt)
OA (1) OA12244A (pt)
PE (1) PE20011178A1 (pt)
PL (1) PL365787A1 (pt)
SK (1) SK14132002A3 (pt)
WO (1) WO2001077107A1 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6004999A (en) * 1998-10-08 2000-04-26 Takeda Chemical Industries Ltd. Agents for retarding change of hormone-dependent cancer into hormone-independentcancer
KR20050063747A (ko) * 2000-07-19 2005-06-28 다케다 야쿠힌 고교 가부시키가이샤 1-치환-1,2,3-트리아졸 유도체, 그 중간체, 및 이들의제조 방법
US20040235748A1 (en) * 2001-04-25 2004-11-25 Yasutaka Igari Agents for preventing postoperative recurrence of premenopausal breast cancer
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
US20040138160A1 (en) * 2001-04-27 2004-07-15 Kenichiro Naito Preventive/therapeutic method for cancer
CA2458452C (en) * 2001-08-10 2011-04-19 Takeda Chemical Industries, Ltd. Gnrh agonist combination drugs
WO2003031442A1 (fr) * 2001-10-05 2003-04-17 Takeda Chemical Industries, Ltd. Composes heterocycliques, derives oxazole, procede permettant de les presenter et leur utilisation
US7812044B2 (en) 2001-11-13 2010-10-12 Takeda Pharmaceutical Company Limited Anticancer agents
WO2003045929A1 (fr) * 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Derive bicyclique, procede de production de ce derive et utilisation correspondante
WO2003059907A1 (fr) * 2002-01-17 2003-07-24 Takeda Chemical Industries, Ltd. Composes heterocycliques azotes : procede de preparation et d'utilisation
IL164799A0 (en) 2002-04-25 2005-12-18 Univ Connecticut Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
ME00076B (me) * 2002-12-16 2011-02-10 Kissei Pharmaceutical Lijek u čvrstom obliku za oralnu primjenu
TW200505913A (en) * 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
AR044098A1 (es) * 2003-04-30 2005-08-24 Hoffmann La Roche Derivados de anilina, su elaboracion, composiciones farmaceuticas y su uso para elaborar medicamentos para el tratamiento del cancer
US7247649B2 (en) 2003-08-13 2007-07-24 Hoffmann-La Roche Inc. Oxazoles, their manufacture and use as pharmaceutical agents
US7259262B2 (en) 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents
US20050186275A1 (en) * 2004-02-23 2005-08-25 Standard Chem. & Pharm. Co. Ltd. Sustained release tamsulosin formulations
TW200531688A (en) 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
TW200612914A (en) * 2004-03-05 2006-05-01 Hoffmann La Roche Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
TW200533346A (en) 2004-03-18 2005-10-16 Hoffmann La Roche Novel ether derivatives, their manufacture and use as pharmaceutical agents
WO2005097777A1 (en) * 2004-04-02 2005-10-20 F. Hoffmann-La-Roche Ag New process for the preparation of diazine derivatives
US7163953B2 (en) * 2004-05-25 2007-01-16 Hoffmann-La Roche Inc. Benzylether derivatives
US7005526B2 (en) * 2004-05-25 2006-02-28 Hoffmann-La Roche Inc. Thioether derivatives
US7618769B2 (en) * 2004-06-07 2009-11-17 Applied Materials, Inc. Textured chamber surface
US7288557B2 (en) 2004-09-21 2007-10-30 Hoffmann-La Roche Inc. Triazole derivatives
TW200616951A (en) * 2004-09-22 2006-06-01 Hoffmann La Roche Indole derivatives, their manufacture and use as pharmaceutial agents
US20060069095A1 (en) * 2004-09-24 2006-03-30 Thomas Hofmeister Azole derivatives
US20060116407A1 (en) * 2004-11-22 2006-06-01 Birgit Bossenmaier Amide derivatives
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
TW200738680A (en) 2005-08-04 2007-10-16 Hoffmann La Roche Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents
EP1915370A1 (en) * 2005-08-08 2008-04-30 F.Hoffmann-La Roche Ag Pyrazole derivatives, their manufacture and their use as pharmaceutical agents
JP2009509998A (ja) * 2005-09-30 2009-03-12 エフ．ホフマン−ラ ロシュ アーゲー ジアジンアゾール誘導体、それらの製造及び薬剤としての使用
WO2008034579A1 (en) * 2006-09-20 2008-03-27 F. Hoffmann-La Roche Ag 2-heterocyclyl-5-phenoxymethylpyridine derivatives as anticancer agents
JPWO2008072634A1 (ja) 2006-12-12 2010-04-02 武田薬品工業株式会社 縮合複素環化合物
US9101617B2 (en) 2007-04-20 2015-08-11 Daido Chemical Corporation Base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion
AR070874A1 (es) 2008-03-12 2010-05-12 Takeda Pharmaceutical Compuesto heterociclico fusionado, una composicion farmaceutica que lo comprende y su uso en el tratamiento del cancer.
AR073679A1 (es) * 2008-09-26 2010-11-24 Takeda Pharmaceutical Prevencion y tratamiento de cancer con la no expresion de lkb1 supresion o mutacion, composicion farmaceutica. usos
AR073680A1 (es) * 2008-09-26 2010-11-24 Takeda Pharmaceutical Prevencion y tratamiento de cancer con la mutacion del gen ras. composicion farmaceutica. uso.
WO2011039952A1 (ja) 2009-09-30 2011-04-07 株式会社サンギ 難溶性物質の水溶解性改善方法
JP5705206B2 (ja) 2010-02-26 2015-04-22 日新化成株式会社 硬カプセルおよびその製造方法
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
JP5909796B2 (ja) 2012-03-02 2016-04-27 株式会社サンギ 難溶性物質の水溶解性改善方法
US9364438B2 (en) 2012-09-26 2016-06-14 Takeda Pharmaceutical Company Limited Process for producing solid particles
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP3795609B1 (en) 2015-07-01 2024-04-03 California Institute of Technology Cationic mucic acid polymer-based delivery systems
EP3238711B1 (en) 2016-04-26 2023-07-12 Mitsubishi Chemical Corporation Base for solid dispersion, production method for solid dispersion using same, and solid dispersion
CA2995617A1 (en) * 2017-11-03 2019-05-03 Universite De Montreal Heterocyclic mitochondrial activity inhibitors and uses thereof
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
CN114217025B (zh) * 2021-12-17 2024-01-23 哈尔滨工业大学 评估空气质量浓度预测中气象数据对其影响的分析方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05506857A (ja) 1990-04-16 1993-10-07 ローヌ―プーラン　ローラー　インターナショナル　（ホウルディングス）インコーポレイテッド Ｅｇｆレセプタチロシンキナーゼを阻害するスチリル―置換単環式および二環式複素アリール化合物
AU3461697A (en) * 1996-07-19 1998-02-10 Takeda Chemical Industries Ltd. Heterocyclic compounds, their production and use

Also Published As

Publication number Publication date
CN1444582A (zh) 2003-09-24
NO20024742L (no) 2002-11-25
CA2404760A1 (en) 2001-10-18
AU2001244726A1 (en) 2001-10-23
EP1268473A1 (en) 2003-01-02
HUP0300434A3 (en) 2004-11-29
KR20020028865A (ko) 2002-04-17
WO2001077107B1 (en) 2001-12-20
US6716863B2 (en) 2004-04-06
PE20011178A1 (es) 2001-11-19
PL365787A1 (en) 2005-01-10
SK14132002A3 (sk) 2003-04-01
EE200200576A (et) 2004-06-15
OA12244A (en) 2006-05-10
CO5261589A1 (es) 2003-03-31
WO2001077107A8 (en) 2003-02-13
US20040024035A1 (en) 2004-02-05
NO20024742D0 (no) 2002-10-02
WO2001077107A1 (en) 2001-10-18
MXPA02009621A (es) 2003-05-14
IL152115A0 (en) 2003-05-29
HUP0300434A2 (hu) 2003-06-28
US20020173526A1 (en) 2002-11-21
CZ20023264A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
BR0109851A (pt) Composto, método para produzir o mesmo ou um sal deste, pró medicamento, composição farmacêutica, método para inibir a tirosina cinase, método para prevenir ou tratar câncer, e, uso de um composto ou de um sal ou pró medicamento deste
BR0014133A (pt) Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
PT1254138E (pt) Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
BR9815171A (pt) Composto inibidor de pde iv aplicável no tratamento de doenças, particularmente de asma, em mamìferos e método para tratar um paciente sofrendo estados doentios.
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
BR0113389A (pt) Compostos que inibem a atividade do fator xa
BR0206670A (pt) Compostos halogenados que exibem agonismo para receptor de trombopoietina
BR0116468A (pt) Compostos de pirrolina substituìda por indazolila como inibidores de cinase
BR0211305A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças ou condições e uso de um composto
DE69940951D1 (de) Nd wachstumshemmende mittel
BR0112370A (pt) Derivados de glutaramida substituìda com ciclopentila como inibidores de endopeptidase neutra
BR9811521A (pt) Composição para tratar ou impedir a glomerulopatia
BR0213094A (pt) Derivados de cromano como ligandos de 5-hidroxi-triptamina-6
ATE238981T1 (de) Antitumorwirkstoffe
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0012419A (pt) Análogos da vitamina d3
BR9814055A (pt) Composto, composição farmacêutica, processo para o tratamento de uma doença alérgica, uso do composto, e, processos para preparar e para produzir um composto
BRPI0407441A (pt) 4-[(2,4-dicloro-5-metóxifenil)amino]-6-alcóxi-3-quinoli nacarbonitrilos para o tratamento de lesão isquêmica
DE69933885D1 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
BRPI0416289A (pt) 4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml)
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
ATE407923T1 (de) Tyrosinderivate als phosphatase inhibitoren
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
PT944618E (pt) Novos compostos de n-benzenossulfonilo-1-prolina processo de preparacao e utilizacao em terapia
BR0111740A (pt) Terapia combinada contra tumores que compreende derivados de distamicina acriloila substituìda e agentes de alquilação

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]